Here are five things to know:
1. The company reached an agreement to settle “substantially all” of the lawsuits related to Infuse, totaling around 6,000 actual and threatened suits in a securities filing.
2. The settlement amounts are confidential. However, the company set aside $300 million for legal fees.
3. The attorneys general in five states sent subpoena documents and requests for information on the sale and marketing of Infuse, and Medtronic has cooperated with the requests; the company set aside funds for inquires last year as well.
4. Last December a St. Louis judge paved the way for a jury trial alleging personal injuries from Infuse, which would reveal the sealed internal documents.
5. The company continues to deny allegations associated with the lawsuits filed by patients, investors and employee whistleblowers.
More articles on orthopedic devices:
Spineology earns FDA clearance for Rampart One system
DePuy Synthes unveils 2 fenestrated screw systems: 6 things to know
Conventus Orthopaedics names new CEO
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
